Three Articles Worth Reading

ASCO Guidelines on HPV Testing in Head and Neck Cancer. The American Society for Clinical Oncology (ASCO) released a guideline endorsement for the College of American Pathologists guidelines surrounding human papillomavirus (HPV) testing in patients with head and neck cancers. The new guidelines call for HPV testing for all newly diagnosed squamous cell oropharyngeal cancers […]

Read More

Fatal Toxicity Associated With Immune Checkpoint Inhibitors

Immune checkpoint inhibitors, including anti-PD-1, anti-PD-L1, and anti-CTLA-4 antibodies, have become an essential component of cancer treatment, and in many tumors, are now considered the standard of care. Because of their mechanism of action, these agents are associated with a unique adverse event (AE) profile driven by immunologic activation. While most immune related adverse events […]

Read More

Improving Healthcare Delivery in Immuno-Oncology via QI Initiatives

Cancer care is complex and rapidly evolving and providing high quality of cancer care for all patients with cancer is an important goal of healthcare providers worldwide. Treatment of cancer has been recently revolutionized with the introduction of immunotherapy, such as immune checkpoint inhibitors, that has demonstrated durable responses and improved survival in various cancers, […]

Read More

Early Evidence of Activity of Trabectedin and Olaparib in Sarcoma

Bone and soft tissue sarcomas comprise a group of biologically diverse tumors that are associated with poor prognosis, despite an increasing number of treatment options that include chemotherapy and targeted therapy. Trabectedin is a safe and effective second-line therapy approved for treatment of advanced soft tissue sarcoma (STS). Poly(ADP ribose) polymerase (PARP) inhibitors are a […]

Read More

Immune Checkpoint Inhibitors Effective in BRAF-Mutant NSCLC

Immune checkpoint inhibitors targeting PD-1 and PD-L1 have become standard first-line therapy for patients with advanced non-small cell lung cancer (NSCLC), but only for patients without activating mutations in EGFR or ALK, as tumors harboring these alterations do not respond well to immunotherapy. In recent years, BRAF-mutated NSCLC has emerged as a recognized molecular subtype […]

Read More

Sequential Brentuxiamb Vedotin For Hodgkin Lymphoma in the Elderly

Outcomes of patients with advanced Hodgkin lymphoma over the age of 60 tend to be inferior compared to younger patients.  One major challenge in treating this patient population is their generally poor health and inability to tolerate toxic chemotherapy regimens. Single-agent therapy with antibody-drug conjugate brentuximab vedotin (BV) has been shown to be an effective […]

Read More

New FDA Approved Indications for Oncology and Hematology in August

First Chemotherapy-Free Treatment for Waldenströms Macroglobulinemia. The combination of the Bruton tyrosine kinase inhibitor ibrutinib (Ibruvica®, Abbvie) and the anti-CD20 monoclonal antibody rituximab (Rituxan®, Genentech) was approved by the United States Food and Drug Administration (FDA) for treatment of patients with Waldenströms macroglobulinemia (WM). Approval of this regimen was based on results from the phase […]

Read More

Baseline steroids

Baseline Steroids Diminish Benefits of PD-(L)1 Blockade in NSCLC

Immunotherapy with PD-1 and PD-L1 immune checkpoint inhibitors has become the standard of care in patients with non-small cell lung cancer (NSCLC) who do not express targetable alterations such as epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK), or ROS1 translocation/rearrangements. Because these agents function by stimulating the immune response, use of immunosuppressive […]

Read More